Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06376695
Other study ID # RADX-P-2407
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 19, 2024
Est. completion date November 2024

Study information

Verified date May 2024
Source Radicle Science
Contact Study Manager
Phone 760-281-3898
Email studymgmt@radiclescience.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on GI health and related health outcomes


Description:

This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States. Eligible participants will (1) endorse a desire for improved bowel habits, less bloating/indigestion, and/or fewer stomach aches/pains (2) have the opportunity for meaningful improvement (at least 20%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded. Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.


Recruitment information / eligibility

Status Recruiting
Enrollment 1100
Est. completion date November 2024
Est. primary completion date July 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 105 Years
Eligibility Inclusion Criteria: - Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities. Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed - Resides in the United States - Endorses a desire for improved bowel habits, less bloating/indigestion, and/or fewer stomach aches/pains - Has the opportunity for at least 20% improvement in their primary health outcome - Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study Exclusion Criteria: - Report being pregnant, trying to become pregnant, or breastfeeding - Unable to provide a valid US shipping address and mobile phone number - Reports current enrollment in another clinical trial - Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) - Unable to read and understand English - Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk. - Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. NYHA (New York Heart Association) Class Ill or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure - Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOls (monoamine oxidase inhibitors), or thyroid products - Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study product - Lack of reliable daily access to the internet

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Radicle GI Health Placebo Control Form 1
Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
Radicle GI Health Active Study Product 1.1 Usage
Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
Radicle GI Health Placebo Control Form 2
Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
Radicle GI Health Active Study Product 2.1 Usage
Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.

Locations

Country Name City State
United States Radicle Science, Inc Del Mar California

Sponsors (1)

Lead Sponsor Collaborator
Radicle Science

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in concentration of at-home (direct-to-consumer) specimen assays either saliva, blood or stool Mean difference in specimen assays as surrogates and/or markers for health outcomes. (Optional; among consented participants only) Potentially include saliva (IgG, cytokines, DHEA-S, Estradiol, Progesterone, Testosterone, Cortisol, Melatonin, CRP) blood (1 drop) (Cortisol, Homocysteine, Ferritin, TSH, HbA1c, Insulin, Vitamin D, DHEA-S, Testosterone, Estradiol, FSH, Total Cholesterol, HDL, LDL, Triglycerides, ApoA1, ApoB). Stool (microbial diversity). Test are optional. Unit of measure will vary based on test selected 6 weeks
Primary Change in GI (Gastrointestinal) Health (1) Mean difference in Gastrointestinal Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Belly Pain 5A (scale 2-25; with higher scores corresponding to more severe abdominal pain) 6 weeks
Primary Change in GI (Gastrointestinal) Health (2) Mean difference in Gastrointestinal Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Gas and Bloating 13A (scale 2-60; with higher scores corresponding to more severe gas/bloating) 6 weeks
Primary Change in GI (Gastrointestinal) Health (3) Mean difference in GI Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Constipation 9A (scale 5-45; with higher scores corresponding to more severe constipation) 6 weeks
Primary Change in GI (Gastrointestinal) Health (4) Mean difference in GI Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Diarrhea 6A (scale 2-30; with higher scores corresponding to more severe diarrhea) 6 weeks
Primary Change in GI (Gastrointestinal) Health (5) Mean difference in GI Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Gastroesophageal Reflux 13A (scale 8-64; with higher scores corresponding to more severe reflux) 6 weeks
Primary Change in GI (Gastrointestinal) Health (6) Mean difference in GI Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Nausea and Vomiting 4A (scale 3-20; with higher scores corresponding to more severe nausea and vomiting) 6 weeks
Secondary Change in feelings of anxiety Mean difference in anxiety score as assessed by PROMIS Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety) 6 weeks
Secondary Change in GI-related Quality of Life (QOL) Mean difference in GI-related QOL as assessed by Digestion-associated QOL Questionnaire (DGLQ) (scale 0%-100%; with higher scores corresponding to worse GI-related QOL) 6 weeks
Secondary Change in mood (emotional distress-depression) Mean difference in emotional distress score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress) 6 weeks
Secondary Minimal clinically important difference (MCID) in GI Health (1) Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Belly Pain 5A (scale 2-25; with higher scores corresponding to more severe abdominal pain) 6 weeks
Secondary Minimal clinically important difference (MCID) in GI Health (2) Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Gas and Bloating 13A (scale 2-60; with higher scores corresponding to more severe gas/bloating) 6 weeks
Secondary Minimal clinically important difference (MCID) in GI Health (3) Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Constipation 9A (scale 5-45; with higher scores corresponding to more severe constipation) 6 weeks
Secondary Minimal clinically important difference (MCID) in GI Health (4) Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Diarrhea 6A (scale 2-30; with higher scores corresponding to more severe diarrhea) 6 weeks
Secondary Minimal clinically important difference (MCID) in GI Health (5) Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Gastroesophageal Reflux 13A (scale 8-64; with higher scores corresponding to more severe reflux) 6 weeks
Secondary Minimal clinically important difference (MCID) in GI Health (6) Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Nausea and Vomiting 4A (scale 3-20; with higher scores corresponding to more severe nausea and vomiting) 6 weeks
Secondary Minimal clinically important difference (MCID) in feelings of anxiety Likelihood of experiencing minimal clinically important difference in feelings of anxiety score as assessed by PROMIS Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety) 6 weeks
Secondary Minimal clinically important difference (MCID) in GI-related QOL Likelihood of experiencing minimal clinically important difference in GI-related QOL score as assessed by Digestion-associated QOL Questionnaire (DGLQ) (scale 0%-100%; with higher scores corresponding to worse GI-related QOL) 6 weeks
Secondary Minimal clinically important difference (MCID) in mood (emotional distress-depression) Likelihood of experiencing minimal clinically important difference in mood score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress) 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT04682860 - Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide Phase 4
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT02923245 - POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound N/A
Completed NCT02547857 - Transvaginal Pelvic Ultrasound in the ED N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02676232 - DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families. N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Recruiting NCT00209807 - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Phase 4
Terminated NCT01410071 - Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction N/A
Terminated NCT01736280 - Evaluating and Treating Potential Research Participants With Digestive Disorders N/A
Enrolling by invitation NCT04104867 - Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy N/A
Completed NCT03574727 - Abdominal Cutaneous Nerve Entrapment Syndrome
Completed NCT04614649 - Right Iliac Fossa Treatment-Turkey Audit
Completed NCT05438654 - Improvement of Diagnostic Approach Using PoCUS for Right Upper Quadrant Abdominal Pain N/A
Completed NCT06423586 - Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS N/A
Completed NCT03558009 - Epidemiological Analysis for Hereditary Angioedema Disease
Terminated NCT03148288 - Vitamin D Supplementation in IBS N/A
Completed NCT03708874 - Pain Management of Emergency Laparoscopic Cholecystectomy in Patients With Acute Cholecystitis
Withdrawn NCT04408872 - EUS vs EGD in Emergency Room Patients Referred for EGD N/A
Recruiting NCT02594774 - Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents N/A

External Links